mcleanap

About mcleanap

This author has not yet filled in any details.
So far mcleanap has created 19 blog entries.

ADVANCED PROTEOME CLOSES FIRST TRANCHE OF PRIVATE PLACEMENT

2017-04-20T20:50:17+00:00

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – OCTBER 31, 2016 - Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) is pleased to announce that it has closed the first tranche of a non-brokered private placement financing (“Private Placement”) announced [...]

ADVANCED PROTEOME CLOSES FIRST TRANCHE OF PRIVATE PLACEMENT2017-04-20T20:50:17+00:00

ADVANCED PROTEOME ANNOUNCES PRIVATE PLACEMENT

2017-04-20T20:51:30+00:00

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia – OCTOBER 25, 2016 - Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) ) announces a non-brokered private placement to raise gross proceeds of up to $600,000 (the "Private Placement"), consisting of [...]

ADVANCED PROTEOME ANNOUNCES PRIVATE PLACEMENT2017-04-20T20:51:30+00:00

ADVANCED PROTEOME THERAPEUTICS CORPORATION OBTAINS OPTION TO LICENSE ANTIBODY CANDIDATES AND COLLABORATES WITH CCAB TO JOINTLY FUND RESEARCH

2017-04-20T20:52:55+00:00

Vancouver, British Columbia, October 19, 2016 (Marketwired) – Advanced Proteome Therapeutics Corporation (APC) (TSX VENTURE: APC) (Frankfurt: 0E8), a biopharmaceutical company dedicated to creating, developing, and commercializing innovative therapies, today announced that it has entered into an exclusive option agreement with the Toronto Recombinant Antibody Centre (TRAC) at the University of Toronto (UT). APC acquired [...]

ADVANCED PROTEOME THERAPEUTICS CORPORATION OBTAINS OPTION TO LICENSE ANTIBODY CANDIDATES AND COLLABORATES WITH CCAB TO JOINTLY FUND RESEARCH2017-04-20T20:52:55+00:00

ADVANCED PROTEOME THERAPEUTICS RETAINS VIRTUS ADVISORY GROUP TO PROVIDE CORPORATE COMMUNICATION SERVICES

2017-04-20T21:05:36+00:00

Vancouver, British Columbia – October 7, 2016 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (0E8.F) is pleased to announce that it has retained Virtus Advisory Group Inc. (“Virtus”), to develop and implement a strategic corporate communications program to increase the Company’s exposure among industry stakeholders and investors across Canada. In connection with [...]

ADVANCED PROTEOME THERAPEUTICS RETAINS VIRTUS ADVISORY GROUP TO PROVIDE CORPORATE COMMUNICATION SERVICES2017-04-20T21:05:36+00:00

ADVANCED PROTEOME THERAPEUTICS CORPORATION AND WILEX SUBSIDIARY HEIDELBERG PHARMA COLLABORATE TO CREATE IMPROVED CANCER THERAPEUTICS

2017-04-20T20:55:51+00:00

Companies will combine Heidelberg Pharma’s proprietary Antibody Targeted Amanitin Conjugates (ATAC) technology with APC’s proprietary site-specific protein modification technology Munich, Germany / Vancouver, Canada, June 14, 2016 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) and Advanced Proteome Therapeutics Corporation, Vancouver, Canada (TSXV: APC) today announced that Heidelberg Pharma GmbH, Ladenburg, Germany, a subsidiary [...]

ADVANCED PROTEOME THERAPEUTICS CORPORATION AND WILEX SUBSIDIARY HEIDELBERG PHARMA COLLABORATE TO CREATE IMPROVED CANCER THERAPEUTICS2017-04-20T20:55:51+00:00

ADVANCED PROTEOME CLOSES PRIVATE PLACEMENT

2017-04-20T20:57:18+00:00

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – MAY 19, 2016 - Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) is pleased to announce that it has closed the non-brokered private placement financing (“Private Placement”) announced April 18, 2016 by [...]

ADVANCED PROTEOME CLOSES PRIVATE PLACEMENT2017-04-20T20:57:18+00:00

ADVANCED PROTEOME ANNOUNCES PRIVATE PLACEMENT

2017-04-20T20:58:49+00:00

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – APRIL 18, 2016 - Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) announces a non-brokered private placement consisting of up to 6,000,000 units (“Units”) at a price of CDN $0.05 per Unit [...]

ADVANCED PROTEOME ANNOUNCES PRIVATE PLACEMENT2017-04-20T20:58:49+00:00

ADVANCED PROTEOME THERAPEUTICS (APC) TO ATTEND BIO-EUROPE SPRING 2016 PARTNERING CONFERENCE

2017-04-20T21:00:19+00:00

VANCOUVER, BC – MARCH 24, 2016 - Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) announces that APC will be attending the 10th Annual International Partnering Conference, at BIO-Europe, Spring 2016, April 4-6, in Stockholm, Sweden. This is Europe’s largest partnering conference within the global biotechnology industry. The conference annually [...]

ADVANCED PROTEOME THERAPEUTICS (APC) TO ATTEND BIO-EUROPE SPRING 2016 PARTNERING CONFERENCE2017-04-20T21:00:19+00:00

ADVANCED PROTEOME THERAPEUTICS CORPORATION ATTENDING JP MORGAN HEALTHCARE CONFERENCE WEEK JANUARY 10-14TH, 2016

2017-04-20T21:02:02+00:00

VANCOUVER, BC – JANUARY 4, 2016 - Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) will be attending the Biotech Showcase Conference, held in San Francisco during the 34th Annual JP Morgan Healthcare Conference week, January 10th – 14th, 2016. The Company is actively looking to partner its extensive IP [...]

ADVANCED PROTEOME THERAPEUTICS CORPORATION ATTENDING JP MORGAN HEALTHCARE CONFERENCE WEEK JANUARY 10-14TH, 20162017-04-20T21:02:02+00:00